Skip to main content
BioNote, Inc. logo

BioNote, Inc. - Investor Relations & Filings

Listed IPO Dec 2022
Ticker · 377740 ISIN · KR7377740006 KO Manufacturing
Open in API
Filings indexed 162 across all filing types
Latest filing 2026-02-20 Report Publication Anno…
Country KR South Korea
Listing KO 377740 · 1 venue

Key figures FY2025

Period ended 2025-12-31 · KRW
Headline annual figures for BioNote, Inc., fiscal year 2025, reported in KRW, with the source filing for each figure.
Total Revenues KRW 118.32B per the Interim / Quarterly Report filed 2026-03-18
Net Income KRW -87.50B per the Interim / Quarterly Report filed 2026-03-18
Total Assets KRW 1555.89B per the Interim / Quarterly Report filed 2026-03-18
Total Equity KRW 1511.25B per the Interim / Quarterly Report filed 2026-03-18
Cash from Ops KRW 14.38B per the Interim / Quarterly Report filed 2026-03-18

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About BioNote, Inc.

https://www.bionote.com/

BioNote, Inc. is a company specializing in in-vitro diagnostics for the animal health industry. It develops, manufactures, and distributes a range of veterinary diagnostic products, including rapid test kits, ELISA kits, point-of-care (POC) analyzers, and biomarker tests. The company's portfolio is based on its research and development of core biological components like antigens and antibodies. Its products are designed for the detection and diagnosis of animal diseases, providing veterinarians with tools for immunochemical and quantitative analysis in clinical settings.

Recent filings

Filing Released Lang Actions
결산실적공시예고(안내공시)
Report Publication Announcement Classification · 100% confidence The document is a short announcement from Bionote regarding the scheduled date for the release of their annual financial results (2025-01-01 to 2025-12-31). It explicitly states the 'expected date of disclosure' (2026-02-25) and does not contain the actual financial report itself. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-02-20 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '신탁계약해지결과보고서' (Report on the Termination of a Trust Agreement) filed by Bionote. It details the termination of a share repurchase trust contract with NH Investment & Securities. This type of filing, which reports the completion or termination of a share buyback program, falls under the category of 'Transaction in Own Shares' (POS) as it relates to the company's repurchase and subsequent holding of its own shares.
2026-01-08 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Korean financial authorities regarding the termination of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This document details the company's decision to terminate a share buyback trust and the subsequent transfer of those shares to the company's direct ownership. This falls under the category of 'Transaction in Own Shares' (POS), which covers share repurchases, buybacks, and related trust management activities.
2026-01-07 Korean
신탁계약에의한취득상황보고서
Major Shareholding Notification Classification · 95% confidence The document is titled '신탁계약등에의한취득상황보고서' which translates to 'Report on Acquisition Status under Trust Contract'. It details the acquisition of shares through a trust contract, including dates, quantities, prices, and the trustee company (NH Investment & Securities). It also includes information on shareholding changes and trust contract details. This type of report is a regulatory disclosure about share acquisitions via trust contracts, typically filed with financial authorities. It is not an annual or quarterly financial report, nor an earnings release, nor a management or board announcement. It is a specific report on share acquisition status under trust agreements, which aligns with notifications about major shareholdings or share acquisition activities. Given the detailed share acquisition data and trust contract information, this fits best under the category of Major Shareholding Notification (MRQ). The document length is 4016 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the classification is MRQ with high confidence.
2025-10-10 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '바이오노트' (Bionote) covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial information, business operations, management discussions, and organizational structure, which is characteristic of an interim/quarterly report. It is not an announcement of a report (RPA) as it contains the full substantive content of the report itself. H1 2025
2025-08-14 Korean
주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korea Exchange regarding a decision to enter into a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 체결 결정). This is a corporate action involving the company buying back its own shares through a trust, which falls under the category of 'Transaction in Own Shares'.
2025-07-08 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.